CoChat

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population

Open access
Mao, Pei-xian, Tang, Yi-lang, Jiang, Feng, Shu, Liang, Gu, Xiuling, Li, Ming, Qian, Mincai, Ma, Cui, Mitchell, Philip B., Cai, Zhuo-ji · 2008 · Depression and Anxiety
Cited by 35

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Escitalopram, the S-enantiomer of citalopram and the most selective of the selective serotonin reuptake inhibitor (SSRI) has been shown to be efficacious in the treatment of major depression in white populations. Our aim in this study was to investigate the efficacy and tolerability of escitalopram in Chinese patients with moderate to severe major depression. Patients who met DSM-IV criteria for a major depressive episode were enrolled in this multicenter, randomized, double-blind, fixed-dose comparison trial. Patients were given escitalopram 10 mg/day or fluoxetine 20 mg/day for 8 weeks. All patients were assessed with the 17-item Hamilton Depression Rating Scale (HAM-D-17) and the Montgomery-Asberg Depression Rating Scale (MADRS). Tolerability was assessed on the basis of adverse effects (measured with a locally developed checklist), regular biochemical tests, and electrocardiograph (ECG) assessments. Two hundred forty patients were enrolled and randomized to escitalopram (123 patients) or fluoxetine (117 patients). The HAM-D-17 total scores of both groups decreased significantly from baseline, but there was no significant difference at week 8 between the two groups (15.8 for escitalopram and 14.7 for fluoxetine; P >.05). There were no significant differences in response rates at all visits after treatment based on either HAM-D-17 or MADRS. A post hoc analysis indicated that escitalopram was superior to fluoxetine on two items of the HAM-D-17: "depressed mood" (P =.023) and "work and interest" (P =.024). The adverse events reported in the escitalopram and fluoxetine groups were comparable, and most were mild to moderate. Both drugs showed good compliance profiles. Escitalopram 10 mg/day is at least as efficacious as fluoxetine 20 mg/day and well tolerated in Chinese patients with major depression, with possible superiority in some core symptoms such as "depressed mood" and "work and interest."

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/da.20222

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 44

  1. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: Author.
  2. Azorin, 2004, Encephale, 30, 158, 10.1016/S0013-7006(04)95427-9 · DOI
  3. Bech, 2004, Int J Neuropsychopharmacol, 7, 283, 10.1017/S1461145704004365 · DOI · Paper page
  4. Burke, 2002, J Clin Psychiatry, 63, 331, 10.4088/JCP.v63n0410 · DOI · Paper page
  5. 1986, Chin J Neuropsychiatry, 19, 70
  6. Colonna, 2005, Curr Med Res Opin, 21, 1659, 10.1185/030079905X65484 · DOI · Paper page
  7. Colonna, 2002, Int J Psychol Clin Prac, 6, 243
  8. Devanand, 2005, Am J Geriatr Psychiatry, 13, 59, 10.1097/00019442-200501000-00009 · DOI
  9. Gorman, 2002, CNS Spectr, 7, 40, 10.1017/S1092852900028595 · DOI · Paper page
  10. Guo, 1994, J Clin Psychol Med, 4, 131
  11. Hamilton, 1960, J Neurol Neurosurg Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
  12. Hong, 2003, J Clin Psychiatry, 64, 921, 10.4088/JCP.v64n0810 · DOI · Paper page
  13. Hu, 2003, Chin J Psychiatry, 36, 242
  14. Hyttel, 1992, J Neural Transm Gen Sect, 88, 157, 10.1007/BF01244820 · DOI · Paper page
  15. Kasper, 2005, Am J Geriatr Psychiatry, 13, 884, 10.1097/00019442-200510000-00008 · DOI
  16. Khan, 2004, Pak J Med Sci, 20, 238
  17. Lalit, 2004, Ind J Psychiatry, 46, 333
  18. Lepola, 2004, Int Clin Psychopharmacol, 19, 149, 10.1097/00004850-200405000-00005 · DOI · Paper page
  19. Lepola, 2003, Int Clin Psychopharmacol, 18, 211, 10.1097/00004850-200307000-00003 · DOI · Paper page
  20. Llorca, 2005, Int J Clin Pract, 59, 268, 10.1111/j.1742-1241.2005.00440.x · DOI · Paper page
  21. Mancama, 2003, CNS Drugs, 17, 143, 10.2165/00023210-200317030-00001 · DOI
  22. Mendlewicz, 2001, Br J Psychiatry, 42, s1, 10.1192/bjp.179.42.s1 · DOI
  23. Mitchell, 2004, Clin Chem Lab Med, 42, 1212, 10.1515/CCLM.2004.243 · doi:10.1515/cclm.2004.243
  24. Montgomery, 2001, Pharmacol Toxicol, 88, 282, 10.1034/j.1600-0773.2001.d01-118.x · DOI · Paper page
  25. Moore, 2005, Int Clin Psychopharmacol, 20, 131, 10.1097/00004850-200505000-00002 · DOI · Paper page
  26. Mork, 2003, Neuropharmacology, 45, 167, 10.1016/S0028-3908(03)00138-2 · DOI · Paper page
  27. . 1996. The global burden of disease. Cambridge, MA: Harvard University Press.
  28. Owens, 2001, Biol Psychiatry, 50, 345, 10.1016/S0006-3223(01)01145-3 · DOI · Paper page
  29. Owens, 2002, CNS Spectr, 7, 34, 10.1017/S1092852900028583 · DOI · Paper page
  30. Poolsup, 2000, J Clin Pharm Ther, 25, 197, 10.1046/j.1365-2710.2000.00281.x · DOI · Paper page
  31. Potkin, 1984, Psychiatry Res, 12, 167, 10.1016/0165-1781(84)90017-9 · doi:10.1016/0165-1781(84)90017-9
  32. Quitkin, 2003, Am J Psychiatry, 160, 734, 10.1176/appi.ajp.160.4.734 · DOI · Paper page
  33. Rush, 2005, Depress Anxiety, 21, 26, 10.1002/da.20051 · DOI · Paper page
  34. Sanchez, 2003, Psychopharmacology (Berl), 167, 353, 10.1007/s00213-002-1364-z · DOI · Paper page
  35. Sanchez, 2004, Psychopharmacology (Berl), 174, 163, 10.1007/s00213-004-1865-z · DOI · Paper page
  36. Sanchez, 2004, Pharmacol Biochem Behav, 77, 391, 10.1016/j.pbb.2003.12.001 · DOI
  37. Shen, 2006, Psychol Med, 36, 257, 10.1017/S0033291705006367 · DOI · Paper page
  38. Si, 2004, Chin J Nerv Ment Dis, 30, 81
  39. 2001. [Pharmacotherapy of depression: An introduction]. In: , , editors. Depressive disorders: Basic and clinical aspects (Chinese). 1st ed. Beijing: Science Press.
  40. Tang, 1998, Chin J Misdiagn, 2, 15
  41. Wade, 2002, Int Clin Psychopharmacol, 17, 95, 10.1097/00004850-200205000-00001 · DOI · Paper page
  42. World Health Organization. 2001. The World Health Report 2001: Mental health: New understanding, new hope. Geneva: Author.
  43. 1993. [Handbook of rating scales in psychiatry]. Changsha, China: Hunan SciTech Publishing.
  44. Zhang, 1998, Chin J Psychiatry, 31, 69

Cited by

See all 35

Metadata

Authors
Mao, P.-X., Tang, Y.-L., Jiang, F., Shu, L., Gu, X., Li, M., Qian, M., Ma, C., Mitchell, P. B., & Cai, Z.-J.
Venue
Depression and Anxiety
Published
2008-01
Volume
25
Issue
1
Pages
46-54
ISSN
  • 1091-4269 (ISSN-L)
  • 1520-6394
OpenAlex
W2024838079
Cited by
35
References
3
FWCI
1.51
Type
journal article
Language
en
Open access
bronze
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 2800 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.